Ipatasertib-NH2 dihydrochloride is primarily used in the field of cancer research, particularly in the study of targeted therapies for various types of cancer. It functions as an inhibitor of the AKT pathway, which is often dysregulated in cancer cells, leading to uncontrolled cell growth and survival. By inhibiting this pathway, it helps in understanding the mechanisms of tumor progression and resistance to conventional treatments. This compound is frequently utilized in preclinical studies to evaluate its efficacy in reducing tumor growth and enhancing the effectiveness of other anticancer agents. Additionally, it serves as a valuable tool in the development of combination therapies, aiming to improve patient outcomes in cancers where the AKT pathway plays a critical role.